Deferred Income Tax Assets, Net of ABVC BIOPHARMA, INC. from 31 Dec 2019 to 30 Sep 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Summary
ABVC BIOPHARMA, INC. quarterly Deferred Income Tax Assets, Net in USD history and change rate from 31 Dec 2019 to 30 Sep 2023.
  • ABVC BIOPHARMA, INC. Deferred Income Tax Assets, Net for the quarter ending 30 Sep 2023 was $34,256, a 97% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Income Tax Assets, Net, Quarterly (USD)
Deferred Income Tax Assets, Net, YoY Quarterly Change (%)

ABVC BIOPHARMA, INC. Quarterly Deferred Income Tax Assets, Net (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2023 $34,256 -$978,903 -97% 30 Sep 2023 10-Q 15 Nov 2023 2023 Q3
Q2 2023 $35,472 -$1,045,231 -97% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $118,191 -$918,639 -89% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $117,110 -$864,802 -88% 31 Dec 2022 10-K 13 Mar 2024 2023 FY
Q3 2022 $1,013,159 -$980,630 -49% 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $1,080,703 -$831,653 -43% 30 Jun 2022 10-Q 15 Aug 2022 2022 Q2
Q1 2022 $1,036,830 -$778,925 -43% 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $981,912 -$808,685 -45% 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $1,993,789 +$345,210 +21% 30 Sep 2021 10-Q 15 Nov 2021 2021 Q3
Q2 2021 $1,912,356 +$332,098 +21% 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $1,815,755 +$328,391 +22% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $1,790,597 +$330,564 +23% 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $1,648,579 30 Sep 2020 10-Q 17 Nov 2020 2020 Q3
Q2 2020 $1,580,258 30 Jun 2020 10-Q 14 Aug 2020 2020 Q2
Q1 2020 $1,487,364 31 Mar 2020 10-Q 29 Jun 2020 2020 Q1
Q4 2019 $1,460,033 31 Dec 2019 10-K 16 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.